Delivering Advanced Therapeutics
CP016 Long Acting Growth Hormone
CP016 is a long acting injection of somatropin (recombinant human growth hormone) that uses Critcal Pharmaceuticals’ proprietary CriticalMix™ drug delivery technology. It is being developed as a once every two week injection and has completed preclinical development.
Patients suffering from growth hormone deficiency are currently treated with a once-daily injection of somatropin, which has a considerable impact upon patients' lives. By reducing the number of injections required with CP016 compared to current medicines, we expect to improve the therapeutic outcome by increasing efficacy through improving patient compliance and reducing the side effect profile.
Human growth hormone deficiency in children results in stunted growth and delayed muscle development and in adults in diminished lean body mass, poor bone density as well as a number of other physical and psychiatric symptoms. In addition to treating growth hormone deficiencies, somatropin is used to treat people with Turners syndrome and HARS, a syndrome associate with HIV infection, as well as certain other muscle wasting diseases due to its role in fat metabolism and muscle development. The market for somatropin products is currently estimated to be $3.1 billion annually.